PRI-724 (Foscenvivint) Clinical Trials

Size	Price	Qty
5mg	USD 270
25mg	USD 817

Clinical Trials

PRI-724 (foscenvivint) has been evaluated in numerous clinical trials across Phase 1, Phase 1/2, and Phase 2 for oncologic and fibrotic hepatic indications, including liver cirrhosis, primary biliary cholangitis, pancreatic adenocarcinoma, myeloid leukemias, and colorectal cancer. Sponsored by pharmaceutical companies such as Prism Pharma Co. Ltd. and Ohara Pharmaceutical Co. Ltd. in collaboration with academic and government entities, trial recruitment statuses across the portfolio range from completed to withdrawn or terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03620474	COMPLETED	Hepatitis C; Hepatitis B; Liver Cirrhoses	Kiminori Kimura, MD	2018-07-24	PHASE1; PHASE2
NCT04688034	Completed	Liver Cirrhosis	Kiminori Kimura MD\|Japan Agency for Medical Research and Development\|Ohara Pharmaceutical Co. Ltd.\|Komagome Hospital	2021-03-15	Phase 1
NCT04047160	Completed	Primary Biliary Cholangitis (PBC)\|Liver Cirrhosis Biliary	Kiminori Kimura MD\|Ohara Pharmaceutical Co. Ltd.\|Japan Agency for Medical Research and Development\|Komagome Hospital	2019-08-29	Phase 1
NCT02413853	WITHDRAWN	Colorectal Adenocarcinoma; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer	University of Southern California	2015-11	PHASE2
NCT02195440	COMPLETED	Hepatitis C Virus-infected Cirrhosis	Komagome Hospital	2014-08	PHASE1
NCT01606579	COMPLETED	Acute Myeloid Leukemia; Chronic Myeloid Leukemia	Prism Pharma Co., Ltd.	2012-07	PHASE1; PHASE2
NCT01764477	COMPLETED	Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer; Pancreatic Adenocarcinoma	Prism Pharma Co., Ltd.	2013-04	PHASE1
NCT01302405	TERMINATED	Advanced Solid Tumors	Prism Pharma Co., Ltd.	2011-02	PHASE1
NCT02195440	Completed	Hepatitis C Virus-infected Cirrhosis	Komagome Hospital\|Prism Pharma Co. Ltd.\|Japan Agency for Medical Research and Development	2014-08	Phase 1
NCT01764477	Completed	Advanced Pancreatic Cancer\|Metastatic Pancreatic Cancer\|Pancreatic Adenocarcinoma	Prism Pharma Co. Ltd.\|inVentiv Health Clinical	2013-04	Phase 1

(data from https://clinicaltrials.gov, updated on 2024-10-10)

Check the PRI-724 (Foscenvivint) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

PRI-724 acts as a selective inhibitor that directly disrupts the binding interaction between β-catenin and CREB-binding protein (CBP), thereby blocking canonical Wnt downstream transcriptional activation and promoting differentiation or apoptosis in target cells. This inhibition of Wnt-mediated stemness and fibrotic gene expression provides the mechanistic basis for suppressing tumor proliferation in pancreatic and colorectal cancers and attenuating extracellular matrix deposition in viral and biliary liver cirrhosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).